Clinical Trials

18 enrolled

Lymphoma, B-Cell

NCT06662227 2026-01-20

Universal CAR-T Cells (REVO-UWD-19) for Refractory and Relapsed B-Cell Tumors

30 enrolled

Leukemia, B-Cell, Lymphoma, B-Cell

NCT07205315 2025-12-26

A Clinical Study Evaluating the Safety and Efficacy of GT801 Injection in Adult Patients With Relapsed/Refractory CD19-positive B-cell Hematologic Malignancies and Autoimmune Hemolytic Anemia

Classical hematologyLymphoidOther hematologic neoplasm

28 enrolled

Anemia, Hemolytic, Autoimmune, Burkitt Lymphoma, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell

NCT07168291 2025-09-17

Novel Bispecific AbTCR (Anti-CD19/CD22)-T Cells in Relapsed or Refractory B-cell Lymphoma

Phase EARLY_PHASE1 Not yet recruiting

3 enrolled

Burkitt Lymphoma, Lymphoma, Follicular, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse

NCT06446128 2025-08-21

A Dose Escalating Study of CD19/CD22/BCMA CAR-T Therapy in Relapsed or Refractory B Cell Non-Hodgkin Lymphoma(NHL)

20 enrolled

Phase EARLY_PHASE1 Not yet recruiting

Lymphoma, Non-Hodgkin, Lymphoma, B-Cell

NCT05779930 2025-08-15

Safety and Feasibility of CD19 CAR T Cells Using CliniMACS Prodigy for Relapsed/Refractory CD19 Positive ALL and NHL

Lymphoma, Non-Hodgkin, Recurrence, Leukemia, B-Cell, Lymphoma, B-Cell, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT06976437 2025-07-10

A Clinical Study of Allogeneic CD19/BCMA CAR-T Cells for the Treatment of R/R B-cell Malignant Tumors

Phase EARLY_PHASE1 Not yet recruiting

21 enrolled

LymphoidPlasma cell

Multiple Myeloma, Lymphoma, B-Cell

NCT07048353 2025-07-02

CAR-T，MTD

15 enrolled

Lymphoma, Lymphoma, B-Cell

NCT06716164 2024-12-04

Safety and Efficacy of Metabolically Armed CD19 CAR-T Cells (Meta10-19) in the Treatment of r/r B-NHL Clinical Research

36 enrolled

Lymphoma, B-Cell

NCT06693973 2024-11-19

An Early Clinical Study Evaluating the Safety and Efficacy of AcNK-Sup003 Cell Injection in the Treatment of Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma

13 enrolled

Phase EARLY_PHASE1 Active not recruiting

Lymphoma, B-Cell

NCT03244176 2024-07-30

AvR-CHOP

28 enrolled

Phase EARLY_PHASE1 Completed

Lymphoma, B-Cell

NCT02981914 2024-04-22

Pilot Study of Pembrolizumab Treatment for Disease Relapse After Allogeneic Stem Cell Transplantation

12 enrolled 11 charts

LymphoidMyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Lymphoma, B-Cell

NCT05673447 2023-08-28

The Study of Anti-CD19 CAR NK Cells in the Treatment of Relapsed/Refractory Diffuse Large B Cell Lymphoma

Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse

NCT05105867 2023-05-10

CD19 Targeted Universal Chimeric Antigen Receptor T Cells Injection for CD19+ Refractory/Relapsed B-cell Malignancies

15 enrolled

Burkitt Lymphoma, Recurrence, Lymphoma, B-Cell

NCT05739227 2023-02-22

Safety and Efficacy of Allogenic CD19-CAR-NK Cells in Treatmenting r/r B-cell Hematologic Malignancies

Phase EARLY_PHASE1 Withdrawn

Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT05015972 2022-11-29

UCAR-T for CD19+ Refractory/Relapsed B Hematologic Malignancies

Phase EARLY_PHASE1 Suspended

Lymphoma, B-Cell

NCT04697290 2022-02-14

CD19/CD20 Dual-CAR-T in B-cell Non-Hodgkin's Lymphoma Patients.

Lymphoma, B-Cell

NCT04412174 2020-06-02

A Study of GC022F CAR-T Cell Immunotherapy for Relapsed or Refractory B- NHL

18 enrolled

Lymphoma, B-Cell

NCT04264039 2020-02-11

Anti-CD19 U-CAR-T Cell Therapy for B Cell Hematologic Malignancies

30 enrolled

Burkitt Lymphoma, Lymphoma, B-Cell

NCT04191941 2019-12-10

Treatment of Hematological Malignancy With Novel CAR-T Cells.

9 enrolled

LymphoidPlasma cell

Burkitt Lymphoma, Multiple Myeloma, Lymphoma, B-Cell

NCT04169932 2019-11-20

The Clinical Study of CD20 CAR-T Cells in Patients With Relapsed and Refractory B Cell Non-Hodgkin Lymphoma

20 enrolled

Lymphoma, Non-Hodgkin, Recurrence, Lymphoma, B-Cell

NCT04156243 2019-11-12

CD19 CARvac T Cells for Patients With Relapsed / Refractory B Cell Malignancies

20 enrolled

Leukemia, B-Cell, Lymphoma, B-Cell

NCT04028440 2019-09-26

γδT Cells Immunotherapy in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma (NHL)

6 enrolled

Lymphoma, Non-Hodgkin, Recurrence, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell, Lymphoma, T-Cell, Peripheral

NCT03690310 2019-01-31

Study of Anti-CD19 CAR NK Cells in Relapsed and Refractory B Cell Lymphoma

9 enrolled

Lymphoma, B-Cell

NCT03824964 2019-01-31

Study of Anti-CD19/CD22 CAR NK Cells in Relapsed and Refractory B Cell Lymphoma

10 enrolled

Lymphoma, B-Cell

NCT03692767 2019-01-30

Study of Anti-CD22 CAR NK Cells in Relapsed and Refractory B Cell Lymphoma

9 enrolled

Phase EARLY_PHASE1 Completed

Lymphoma, B-Cell

NCT02144623 2017-03-03

PREVAIL

4 enrolled

Phase EARLY_PHASE1 Terminated

Lymphoma, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell

NCT00515138 2012-04-12

A Pilot Study of Standard-Dose Rituximab, Ifosfamide, Carboplatin and Etoposide (RICE) Plus Bortezomib (Velcade) in a Dose-Escalating Fashion for Patients With Relapsed or Primary Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma Who Are Candidates for Autologous Stem Cell Transplant

7 enrolled